A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Kestrel Therapeutics, Inc.
Revolution Medicines, Inc.
Seagen Inc.
Pfizer
City of Hope Medical Center
Novartis
Chongqing Precision Biotech Co., Ltd
Elicio Therapeutics
Columbia University
UTC Therapeutics Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
Chongqing Precision Biotech Co., Ltd
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Novartis
MacroGenics
Abramson Cancer Center at Penn Medicine
Northwestern University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Duke University
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Cancer Research UK
Roger Williams Medical Center
National Cancer Institute (NCI)
Case Comprehensive Cancer Center